Johnson & Johnson

Social media sentiment, last 30 days

Average tone of posts mentioning JNJ, from −1 (all negative) to +1 (all positive). Latest day: −0.50 across 22 mentions.

• Press releaseOct 20, 7:45 AM ETBusiness Wire

  Johnson & Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half

• Press releaseOct 19, 8:00 AM ETPRNewswire

  Johnson & Johnson announces new data showing TREMFYA® (guselkumab) is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula

• Press releaseOct 17, 9:29 PM ETBusiness Wire

  JNJ Investors with $100,000 in Losses Have Opportunity to Join Johnson & Johnson Fraud Investigation with SBS Law

• Press releaseOct 14, 3:02 PM ETPRNewswire

  Johnson & Johnson Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Johnson & Johnson (JNJ)

• NewsOct 14, 1:45 PM ETPriya Nigam

  Johnson & Johnson Q3 Sets 'Negative Tone For Broader Pharma Sector': Analysts

• NewsOct 14, 1:06 PM ETAvi Kapoor

  These Analysts Cut Their Forecasts On Johnson & Johnson After Q3 Results

• NewsOct 14, 9:21 AM ETMark Putrino

  Stock of the Day: Is this the Bottom for Johnson & Johnson?

• NewsOct 13, 9:21 PM ETShivdeep Dhaliwal

  Bank of America, Johnson & Johnson, Six Flags Entertainment, Citigroup and Applied Materials: Why These 5 Stocks Are on Investors' Radars Today

• NewsOct 13, 3:17 PM ETVandana Singh

  Johnson & Johnson Tops Q3 Estimates, Raises 2026 Outlook on Cancer Drug Strength (UPDATED)

• NewsOct 13, 2:23 PM ETPiero Cingari

  QUICK SPARK: J&J Eyes Worst Day Since April 2025 with MedTech Miss

• NewsOct 13, 1:35 PM ET

  10 Health Care Stocks With Whale Alerts In Today’s Session

• NewsOct 13, 1:24 PM ET

  'J&J Is Leaning Toward Spinning Out Its Hips-And-Knees Business' - The Wall Street Journal

• NewsOct 13, 12:59 PM ETPiero Cingari

  Chip Stocks Slide as South Korea's KOSPI Plunges, J&J Sinks 6%: Stock Market Today

• NewsOct 13, 9:47 AM ET

  Transcript: Johnson & Johnson Q3 2026 Earnings Conference Call

• NewsOct 13, 7:11 AM ET

  Earnings Scheduled For October 13, 2026

• Press releaseOct 13, 6:25 AM ETBusiness Wire

  Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2026

• Press releaseOct 13, 6:20 AM ETBusiness Wire

  Johnson & Johnson reports Q3 2026 results, raises 2026 guidance

• NewsOct 13, 1:48 AM ETRishabh Mishra

  Stock Market: Will S&P 500 Open Up or Down Today?

• Press releaseOct 12, 4:05 PM ETPRNewswire

  New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroups

• Press releaseOct 12, 4:05 PM ETPRNewswire

  TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

• NewsOct 12, 3:30 PM ETKaustubh Bagalkote

  JPMorgan Chase Could Swing $28 Billion After Earnings

• NewsOct 12, 12:24 PM ETChris Katje

  Dow Jones Industrial Average Gets Spotlight: 5 Earnings Reports Representing 25% of ETF’s Assets On Deck

• Press releaseOct 12, 7:29 AM ETPRNewswire

  After a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings Reports

• Press releaseOct 9, 7:00 AM ETPRNewswire

  New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

• Press releaseOct 7, 9:59 AM ETGlobe Newswire

  2026 Takes a Promising Turn in the Fight Against Cancer as Five Advances Offer New Hope

• Press releaseOct 2, 6:00 AM ETPRNewswire

  Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy

• Press releaseOct 1, 7:45 AM ETBusiness Wire

  New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause

• NewsSep 29, 1:01 PM ETPriya Nigam

  Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss

• Press releaseSep 29, 8:03 AM ETPRNewswire

  Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)

• NewsSep 25, 11:03 AM ETVandana Singh

  Johnson & Johnson Clinical Trials Show Progress Across Key Therapies

• Press releaseSep 25, 7:30 AM ETPRNewswire

  Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) study

• Press releaseSep 25, 7:00 AM ETPRNewswire

  Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma

• Press releaseSep 23, 9:46 AM ETPRNewswire

  New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma

• Press releaseSep 22, 8:00 AM ETBusiness Wire

  DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026

• NewsSep 21, 1:08 PM ETVandana Singh

  Johnson & Johnson Drug Shows Improved Mania Symptoms in Bipolar Patients

• Press releaseSep 21, 8:00 AM ETPRNewswire

  CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 study

• NewsSep 15, 4:57 PM ETChris Katje

  Senator Bets on Small Cap Stocks Ahead of Likely Rate Hike: Why That Could be Risky

• NewsSep 11, 3:56 PM ETChris Katje

  Richest NFL Team Owners List: Who’s Most Connected to Stock Market?

• NewsJul 14, 11:55 AM ETChris Katje

  Johnson & Johnson Q2 Preview: Stock Near All-Time Highs, Market Expert Sees Rally to $282 – ‘Continue Their Winning Ways’

• NewsJul 14, 8:40 AM ETAvi Kapoor

  How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q2 Earnings

• NewsMay 15, 2:46 PM ETChris Katje

  Congressman A Big Fan Of Dividend Reinvestments: Here's His Core Blue Chip Stocks

• NewsMay 15, 12:24 PM ET

  One Blue-Chip Stock Is Up 11% While the S&P 500 Struggles

• NewsJan 20, 8:37 AM ETAvi Kapoor

  How To Earn $500 A Month From Johnson & Johnson Stock Ahead Of Q4 Earnings

• NewsJan 6, 12:29 PM ETChris Katje

  Congressman Chases Dividend Stocks: The Four Dow Jones Components He Bought In December

• NewsJan 2, 5:06 PM ETChris Katje

  Dogs Of The Dow: 10 High-Yield Stocks With Dividends Up To 6.8% - Including Several Warren Buffett Favorites

• NewsDec 30, 8:45 AM ETAvi Kapoor

  State Street To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Tuesday